Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BioMarin Pharmaceutical (BMRN)

BioMarin signs settlement and license deal with Ascendis, with royalties on TransCon CNP sales

Neutral Impact 3 of 5 legal/regulatory Written later

BioMarin entered into a Settlement and License Agreement with Ascendis Pharma on September 24, 2026, replacing an August 2026 binding term sheet. Ascendis receives a non-exclusive license to BioMarin patents covering TransCon CNP (navepegritide, Yuviwel), and BioMarin receives royalties on net sales until May 2030. The filing says the parties will dismiss all pending litigation between them over the patents, and it does not disclose dollar amounts.

Key points

  • Agreement dated September 24, 2026, deemed effective August 28, 2026, and supersedes the term sheet reported on August 31, 2026
  • Royalty of 20% of annual net sales in the United States and 18% in the EU, Brazil and South Korea, until May 2030
  • Pending litigation between the parties relating to the BioMarin patent rights to be dismissed with prejudice
  • Ascendis agreed not to challenge BioMarin's patent rights; no dollar figures disclosed

The filing

CompanyBioMarin Pharmaceutical (BMRN)
Form8-K, current report
Filed with the SECSep 30, 2026, 4:15 PM ET
Accession number0001628280-26-063981

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.